Literature DB >> 24937555

Partial compliance with antipsychotics and its impact on patient outcomes.

Meera Narasimhan1, Chi Un Pae, Natasha Masand, Prakash Masand.   

Abstract

Partial compliance with antipsychotic medications is a common and complex phenomenon that is underestimated by physicians. The consequences of partial compliance include an increased risk of relapse, rehospitalization and suicide attempts. Stigma, negative attitudes towards medications, cognitive impairment and diminished insight negatively impact treatment adherence. Oral atypical antipsychotics may improve both insight and cognitive function, but compliance with these agents is not assured. Depot conventional antipsychotics ensure medication delivery but are associated with side-effects such as EPS and dysphoria that decrease compliance. Long-acting atypicals provide significant symptom improvement, foster adherence and may help achieve improvement in insight and cognition. Addressing issues of partial and non-compliance is a significant consideration in relapse prevention strategies for patients with schizophrenia, given the devastating consequences associated with psychotic relapses.

Entities:  

Keywords:  Adherence; antipsychotic; partial compliance; psychosis; schizophrenia

Year:  2007        PMID: 24937555     DOI: 10.1080/13651500600973568

Source DB:  PubMed          Journal:  Int J Psychiatry Clin Pract        ISSN: 1365-1501            Impact factor:   1.812


  7 in total

1.  Comparative effectiveness of long-acting antipsychotics: issues and challenges from a pragmatic randomised study.

Authors:  G Ostuzzi; C Barbui
Journal:  Epidemiol Psychiatr Sci       Date:  2015-10-30       Impact factor: 6.892

2.  Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review.

Authors:  Prakash S Masand; Miquel Roca; Martin S Turner; John M Kane
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

3.  Oral Antipsychotic Versus Long-Acting Injections Antipsychotic in Schizophrenia Spectrum Disorder: a Mirror Analysis in a Real-World Clinical Setting.

Authors:  Nicola Poloni; Marta Ielmini; Ivano Caselli; Giulia Lucca; Alessandra Gasparini; Alessandra Gasparini; Giorgia Lorenzoli; Camilla Callegari
Journal:  Psychopharmacol Bull       Date:  2019-06-20

4.  Time to rehospitalization in involuntarily hospitalized individuals suffering from schizophrenia discharged on long-acting injectable antipsychotics or oral antipsychotics.

Authors:  Ching-Hua Lin; Hung-Yu Chan; Fu-Chiang Wang; Chun-Chi Hsu
Journal:  Ther Adv Psychopharmacol       Date:  2022-03-23

5.  Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy.

Authors:  Giovanni Ostuzzi; Maria Angela Mazzi; Samira Terlizzi; Federico Bertolini; Andrea Aguglia; Francesco Bartoli; Paola Bortolaso; Camilla Callegari; Mariarita Caroleo; Giuseppe Carrà; Mariangela Corbo; Armando D'Agostino; Chiara Gastaldon; Claudio Lucii; Fabio Magliocco; Giovanni Martinotti; Michela Nosé; Edoardo Giuseppe Ostinelli; Davide Papola; Marco Piero Piccinelli; Alberto Piccoli; Marianna Purgato; Tommaso Tabacchi; Giulia Turrini; Mirella Ruggeri; Corrado Barbui
Journal:  PLoS One       Date:  2018-08-02       Impact factor: 3.240

6.  Long-Acting Injectable Second-Generation Antipsychotics Improve Negative Symptoms and Suicidal Ideation in Recent Diagnosed Schizophrenia Patients: A 1-Year Follow-up Pilot Study.

Authors:  Valentina Corigliano; Anna Comparelli; Iginia Mancinelli; Benedetta Montalbani; Dorian A Lamis; Antonella De Carolis; Denise Erbuto; Paolo Girardi; Maurizio Pompili
Journal:  Schizophr Res Treatment       Date:  2018-08-30

Review 7.  Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations.

Authors:  Markku Lähteenvuo; Jari Tiihonen
Journal:  Drugs       Date:  2021-07-01       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.